

Corrections

FX Enzyme Controls the Adhesive Properties of CRC

In the article on how FX enzyme controls the adhesive properties of CRC in the September 15, 2004 issue of *Cancer Research* (1), some of the labeling in Figures 7 and 10 was incorrect. The corrected figures are below.

- Zipin A, Israeli-Amit M, Meshel T, Sagi-Assif O, Yron I, Lifshitz V, Bacharach E, Smorodinsky NI, Many A, Czernilofsky PA, Morton DL, Witz IP: Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. *Cancer Res* 2004;64:6571–8.




Fig. 7. Expression of FX mRNA, FX protein and of sLe-a by SW620 cells stably transfected with FX siRNA. A, FX mRNA. Expression was determined by Northern blot analysis. Values represent the ratio between the signal of FX mRNA in the cells and the signal of 18S rRNA in the same cell sample. B, FX protein. Expression was determined as in Fig. 2A. C, sLe-a. Expression was determined as in Fig. 2B. A representative experiment (of three performed) is presented (360 cells = control cells; 205 cells = FX siRNA transfectants). M = mean fluorescence; %pos = % positive cells.




Fig. 10. Expression of fucosylated proteins by SW620 cells stably transfected with FX siRNA. Lysates of control (360) and FX siRNA (205) transfected cells were assayed for the expression of fucosylated proteins by Western blot analysis using horseradish peroxidase-conjugated Ulex europaeus agglutinin I. Expression of FX protein in the two cell populations was determined as in Fig. 2A. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading control.

Chromosome 11q LOH in Human Breast Cancer

In the article on chromosome 11q LOH in human breast cancer in the September 1, 1994 issue of *Cancer Research* (1), the name of one of the contributing authors was misspelled. The correct spelling is Robert Winqvist.

- Hampton GM, Mannermaa A, Winqvist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans GA: Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3 *Cancer Res* 1994;54:4586–9.

p110δ Isoform of PI3 Kinase in Tumor Endothelium

In the article on p110δ Isoform of PI3 Kinase in Tumor Endothelium in the July 15, 2004 issue of *Cancer Research* (1), the name of one of the contributing authors, Jeffrey Brousal, was missing. The correct list of authors should read: Ling Geng, Jiahuai Tan, Eric Himmelfarb, Aaron Schueneman, Ken Niemann, Jeffrey Brousal, Allie Fu, Kyle Cuneo, Edward A. Kesicki, Jennifer Treiberg, Joel S. Hayflick, and Dennis E. Hallahan. Dr. Brousal's affiliation is the Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.

- Geng L, Tan J, Himmelfarb E, Schueneman A, Niemann K, Brousal J, Fu A, Cuneo K, Kesicki EA, Treiberg J, Hayflick JS, Hallahan DE. A specific antagonist of the p110δ catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction. *Cancer Res* 2004;64:4893–9.

Glioblastoma-Founding Human Neural Precursors

In the article on glioblastoma-founding human neural precursors in the October 1, 2004 issue of *Cancer Research* (1), the e-mail address of R. Galli should have been included in the requests for reprints section. Dr. Galli's e-mail address is galli.rossella@hsr.it.

- Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res* 2004;64:7011–21.

NF-κB in Squamous Cell Carcinoma

In the article on NF-κB in squamous cell carcinoma in the September 15, 2004 issue of *Cancer Research* (1), the entries in Tables 1 and 2 indicating NF-κB modulated genes should have been boldfaced. The corrected Tables 1 and 2 are reproduced below.

- Loercher A, Lee TL, Ricker JL, Howard A, Geoghegan J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS Jr, Van Waes C: Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. *Cancer Res* 2004;64:6511–23.

Table 1 Selected list of genes increased with tumor progression

Function Gene	Symbol	Clone ID	NF-κB Association	Fold change	
				LY-2/Ker	LY-2/IκB-αM
Cell cycle/growth					
<i>Cyclin D1</i> *	<i>Ccnd1</i>	H3084D05	Target gene	3.351	-2.266
<i>Cyclin D2</i> *	<i>Ccnd2</i>	H3152D01	Target gene	2.957	-2.05
<i>Growth arrest specific 5</i> *	<i>Gas5</i>	H3113A12		6.304	-7.813
<i>Milk fat globule-EGF factor 8</i> *	<i>Mfge8</i>	H3126F11	Target gene	2.594	-3.525
<i>Protein phosphatase 3</i> *†	<i>Ppp3cb</i>	H3065C08	Inhibitor of NF-κB	3.117	-2.231
<i>Proliferating cell nuclear antigen</i> *	<i>Pcna</i>	H3021F12	Target gene	5.775	-2.811
Apoptosis					
<i>Baculoviral IAP repeat</i> *	<i>Birc2</i>	H3074A02	Target gene	9.154	-6.013
<i>Bcl-2 related ovarian killer</i> *†	<i>Bok1</i>	H3081D02		1.994	-3.461
<i>Immediate early response 3</i> *	<i>Ier3</i>	H3057B07	Target gene	2.865	-3.851
<i>Transformation related protein</i> *†	<i>Trp53</i>	H3142D07	Target gene	2.9	-4.142
<i>Uchrp</i> *	<i>Uchrp</i>	IMAGE:605056		2.188	-4.353
Inflammation/angiogenesis					
<i>Colony stimulating factor 1</i> *	<i>Csf1</i>	H3057D05	Target gene	14.639	-5.574
<i>Complement component 3</i> *†	<i>C3</i>	H3054A08	Target gene	5.145	-8.303
<i>FGF receptor</i> *	<i>Fgfr4</i>	IMAGE:406823	Target gene	1.982	-1.991
<i>Gro 1 oncogene</i> *	<i>Gro1</i>	H3051F10	Target gene	12.394	-4.094
<i>Histocompatibility 2-L</i> *	<i>H2-L</i>	H3096A12	Target gene	2.342	-3.431
<i>Histocompatibility 2-D</i> *	<i>H2-D</i>	H3141B11	Target gene	2.968	-3.927
<i>Interferon receptor</i> *	<i>Ifnar</i>	H3118F09	Inhibitor of NF-κB	4.5	-3.054
<i>Lymphocyte antigen complex</i> *	<i>Ly6e</i>	H3027D05	Inducer of NF-κB	4.029	-2.613
Metastasis					
<i>Integrin α 3</i> *†	<i>Itga3</i>	H3137A03	Inducer of NF-κB	15.597	-3.917
<i>Laminin α 5</i> *†	<i>Lama5</i>	H3002G01	Target gene	2.272	-2.967
<i>Laminin receptor 1</i>	<i>Lamr1</i>	H3075G08		2.169	-1.619
<i>Plasminogen activator, tissue</i>	<i>Plat</i>	H3080H11	Target gene	2.667	-2.487
<i>Procollagen type 5 α 2</i>	<i>Col5a2</i>	H3156E09	Target gene	5.103	-2.094
<i>Syndecan 1</i> *	<i>Sdc1</i>	H3013F05	Target gene	2.948	-2.034
Metabolism					
<i>ATPase H+ transport</i> *†	<i>Atp6b</i>	H3120H04	Inhibitor of NF-κB	2.247	-2.858
<i>Branched chain ketoacid dehyd</i> *	<i>Bckdk</i>	H3136B09		2.455	-3.042
<i>Choline kinase</i> *†	<i>Chk</i>	H3088E07	Inducer of NF-κB	6.662	-3.252
<i>Cytochrome p450</i> *	<i>Cyp1b1</i>	J0216F07	Target gene	22.289	-4.286
<i>Glutathione-S-transferase</i> *	<i>Gstm1</i>	H3133A06	Target gene	3.037	-3.061
<i>Low density lipoprotein receptor</i> *	<i>Ldlr</i>	H3014C04	Target gene	2.689	-3.226
<i>Mannose-6-phosphate receptor</i> †	<i>M6pr</i>	H3092C05	Inhibitor of NF-κB	6.303	-3.612
<i>Potassium intermediate</i> *	<i>Kcnn4</i>	H3054H04		2.778	-2.197
<i>Solute carrier family 12</i> *†	<i>Slc12a2</i>	H3077B02		2.551	-2.145
Stress response					
<i>Heat shock protein, 70 kDa</i> *	<i>Hspa5</i>	H3032A08	Activates NF-κB	14.303	-6.369
<i>Heat shock protein 84 kDa</i> *	<i>Hsp84</i>	H3042G07	Activates NF-κB	3.437	-7.198
<i>Heat shock protein 86 kDa</i> *	<i>Hsp86</i>	H3023G01	Activates NF-κB	2.61	-2.34
<i>Heat shock protein cognate 70</i> *	<i>Hsc70</i>	H3133H01	Binds NF-κB	3.42	-10.229
<i>Superoxide dismutase</i> *	<i>Sod1</i>	H3130B11	Target gene	4.784	-2.145
Signal transduction					
<i>AXL receptor tyrosine kinase</i> *†	<i>Axl</i>	H3152F05	Inhibitor of NF-κB	2.459	0.938
<i>CD97 (EGF-TM7)</i> *†	<i>Cd97</i>	H3032G06		2.283	-1.352
<i>Interleukin-1 receptor associated</i> *	<i>Il1rak</i>	H3042E08	Activates NF-κB	1.999	-1.296
<i>Frizzled 7 homolog</i>	<i>Fzd7</i>	H3031A03		2.717	-0.843
<i>Growth arrest & DNA damage specific</i> *	<i>Gadd45g</i>	H3054C02	Activates NF-κB	3.144	-1.407
<i>Growth factor receptor bound</i> *	<i>Grb2</i>	H3153D02	Activates NF-κB	2.483	-2.341
<i>N-myc downstream regulated</i> *	<i>Ndr2</i>	G0110H06	Inhibits p50	2.248	-2.039
<i>P13 kinase regulatory</i> *	<i>Pik3r1</i>	H3067B08	Activates NF-κB	4.206	-3.539
<i>Protein tyrosine phosphatase</i> *†	<i>Ptpn13</i>	H3118G02	Inhibitor of NF-κB	2.844	-9.071
<i>Ras p21 protein activator 3</i> *†	<i>Rasa3</i>	H3054E01	Activates NF-κB	3.223	-2.71
<i>Ras-related C3</i> *	<i>Rac1</i>	IMAGE:477981		2.042	-3.875
<i>Transferrin receptor</i> *	<i>Trfr</i>	H3059G03		2.216	-1.145
Nuclear proteins/transcription factors					
<i>Activating transcription factor</i> †	<i>Atf2</i>	J0221F08		1.606	-2.696
<i>Breast cancer, early onset</i> †	<i>Brca2</i>	H3069F08		2.216	-0.604
<i>Butyrate response factor</i> *	<i>Brf2</i>	H3015E08		2.072	-2.008
<i>High mobility group AT</i> *	<i>Hmgal</i>	H3029B11	Target gene	2.816	-2.591
<i>Jerky</i> *	<i>Jrk</i>	H3119F06		2.849	-3.329
<i>Myelocytomatosis oncogene</i> *	<i>Myc</i>	H3089H11	Target gene	2.224	-2.42
<i>Nuclear factor κB p105</i> *	<i>Nfkb1</i>	H3072E09		2.919	-1.443
<i>Sex comb on midleg-like 1</i> †	<i>Scm1l</i>	H3113B01		2.355	-1.154
<i>Yes-associated protein 65 kDa</i>	<i>Yap</i>	H3089H07		2.072	-1.746
RNA processing					
<i>DEAD box protein 3</i> *	<i>Ddx3</i>	H3018F11		2.976	-2.055
<i>DJ-1 protein</i> †	<i>DJ-1</i>	H3150D06		3.155	-4.611
<i>FGF inducible 14</i>	<i>Fin14</i>	H3018G01		2.358	-3.355
<i>Nuclear ribonuclease</i>	<i>Hnrpa1</i>	H3111H11		4.926	-2.785
<i>RNA polymerase 1-1</i> *	<i>Rpo1-1</i>	H3049D09		2.703	-2.328
Protein synthesis/modification					
<i>ERO1 like</i> *†	<i>Ero1l</i>	H3126B01		2.529	-2.456
<i>Ribosomal protein L27a</i>	<i>Rpl27a</i>	H3009B05		2.183	1.369

Table 1 *Continued*

Function Gene	Symbol	Clone ID	NF- κ B Association	Fold change	
				LY-2/Ker	LY-2/I κ B-aM
<i>Ribosomal protein L8</i>	Rpl8	H3141F09		2.778	1.005
<i>Ribosomal protein S18*</i>	Rps18	H3006C11		2.487	-2.424
<i>Ubiquitin activating enzyme E1</i>	Ube1x	H3022E03	Phosphorylates κ B	5.313	-3.139
<i>Ubiquitin B</i>	Ubb	H3138A08	Labels κ B	8.144	-1.171
<i>Ubiquitin conjugating enzyme E2</i>	Ube2h	H3057B09	Phosphorylates κ B	3.333	-1.199
<i>Ubiquitin conjugating enzyme E3†</i>	Ube3a	H3102B01	Phosphorylates κ B	4.878	-5.096
<i>Ubiquitin specific protease 9†</i>	Usp9x	H3139F12		3.769	-3.175
Structural proteins					
<i>Alpha tropomyosin*</i>	Tpm1	H3120G06	Binds p65	2.421	-4.36
<i>Cadherin*</i>	Cdh3	H3018F05	Inflammatory	2.328	-2.706
<i>Capping protein α 2</i>	Cappa2	H3085F12		14.293	-7.458
<i>Dystroglycan 1*</i>	Dag1	H3008B05	Activates NF- κ B	2.593	-4.738
<i>Epithelial protein lost*†</i>	Eplin	H3153C05	Activates NF- κ B	2.066	-2.971
<i>Fascin homolog 1*</i>	Fscn1	H3006D08		2.315	-2.581
<i>Four and a half LIM domains*</i>	Fhl2	H3033C07		2.169	-1.189
<i>Keratin complex 1 acidic*</i>	Krt1-18	H3021B02	Target gene	3.105	-5.517
<i>Keratin complex 2 basic*</i>	Krt2-8	H3031C01		2.094	-5.568
<i>PDZ and LIM domain 1*</i>	Pdlim1	J0824B03		5.7	-3.775
<i>Protocadherin 7*†</i>	Pcdh7	H3067F12	Inflammatory	6.556	-1.026
<i>Thymopoietin*</i>	Tmpo	H3096B08		9.939	-8.153
Other					
<i>Globin inducing factor†</i>	Gbif	H3053F12		2.003	1.002
<i>Metallothionein 2</i>	Mt2	H3013D11	Inhibits I κ B degradation	2.145	-3.029
<i>Next to the Brca1*†</i>	Nbr1	H3061D04		2.367	-1.888
<i>RAN binding protein*</i>	Ranbp9	H3013A10	Accumulates I κ B α	2.87	-3.189
<i>Repeat family 3 gene*</i>	Llrep3	H3107F07		3.556	-7.704
<i>Ring finger protein 19*</i>	Rnf19	H3153A08	Activates NF- κ B	2.148	-4.402
<i>Sema domain, immunoglobulin*†</i>	Sema3f	H3134D09		2.191	-1.667
<i>Suppressor of Lec15†</i>	Supl15h	H3090D12		2.001	-1.383
<i>TGF β inducible transcript*</i>	Tgfb1i1	H3122H01		3.068	-2.974

NOTE. Total number of genes regulated by NF- κ B = 105/167. Total number of genes previously associated with NF- κ B = 67/167.

* Genes containing κ B site in promoter region.

† Genes containing ACTACAG motif in coding sequence.

Table 2 Selected list of genes decreased with tumor progression

Function Gene	Symbol	Clone ID	NF-κB association	Fold change	
				LY2/Ker	LY2/IkB-αM
Cell cycle/growth					
<i>C-src tyrosine kinase*</i>	<i>Csk</i>	L0237H04		-2.693	2.358
<i>Calmodulin</i>	<i>Calm</i>	H3006H05	Activates NF-κB via IKK	-2.554	2.42
<i>Cell division cycle homolog 25a</i>	<i>Cdc25a</i>	H3050E04		-2.341	2.269
<i>Cell division cycle homolog 45</i>	<i>Cdc45l</i>	H3003E07		-2.032	2.029
<i>Cyclin C</i>	<i>Ccnc</i>	C0117F09		-2.739	2.418
<i>Cyclin E2*</i>	<i>Ccne2</i>	C0186A01		-2.309	2.155
<i>Cyclin dependent kinase 4</i>	<i>Cdk4</i>	H3147D06	Target gene of NF-κB	-2.734	2.05
<i>Cyclin dependent kinase inhibitor*</i>	<i>Cdkn1c</i>	H3097D03		-5.208	2.913
<i>Platelet derived growth factor*</i>	<i>Pdgfa</i>	H3146C02		-2.15	2.906
Apoptosis					
<i>ATP binding cassette*</i>	<i>Abcd3</i>	H3143E03	NF-κB site in promoter	-2.89	2.535
<i>Bcl2/adenovirus E1B</i>	<i>Bnip3</i>	H3103B07	Transient inhibitor of NF-κB	-2.364	2.436
<i>Fas associating w/death domain</i>	<i>Fadd</i>	H3095D08	Inducer of NF-κB	-3.597	2.975
Inflammation/angiogenesis					
<i>Coagulation factor III*†</i>	<i>F3</i>	H3014G02	Activates NF-κB via IKK	-4.672	3.858
<i>Interleukin 17 receptor</i>	<i>Il17r</i>	H3008A03	Activates NF-κB via MAPK	-3.021	3.048
<i>Interleukin 2 receptor</i>	<i>Il2ra</i>	J0052C08	NF-κB site in promoter	-2.262	2.207
<i>Lymphocyte antigen 6 complex</i>	<i>Ly6</i>	H3115A08	Inducer of NF-κB	-5.617	3.311
<i>Prothymosin β</i>	<i>Ptmb4</i>	H3143A02		-21.739	8.858
Metastasis					
<i>A disintegrin/MMP</i>	<i>Adamts1</i>	H3034B07		-2.695	2.736
<i>Cadherin 1*</i>	<i>Cdh1</i>	H3076B06	Associated with inflammation	-2.597	2.313
<i>Kangai 1†</i>	<i>Kail</i>	H3154D02	Target gene of NF-κB	-2.816	2.139
<i>Lipocalin 2</i>	<i>Lcn2</i>	H3083G02	Associated with inflammation	-2.506	11.235
<i>Procollagen type I α</i>	<i>Col1a2</i>	H3125D01		-4.901	2.886
<i>Procollagen type II α</i>	<i>Col2a1</i>	H3026G09		-6.896	2.139
<i>Procollagen type III α</i>	<i>Col3a1</i>	H3005D11	Inducer of NF-κB	-3.205	4.268
<i>Secreted acidic C-rich</i>	<i>Sparc</i>	H3026D08		-8.928	2.872
<i>Tissue inhibitor of MMPs</i>	<i>Timp3</i>	H3031E01	Two NF-κB sites in promoter	-3.3	3.289
Metabolism					
<i>ATPase, type 11A†</i>	<i>Atp11a</i>	H3097B05		-2.888	2.734
<i>ATP synthase H+ transport</i>	<i>Atp5j2</i>	H3118C01	Inhibitor of NF-κB	-2.191	2.111
<i>Glutathione peroxidase*</i>	<i>Gpx3</i>	J0088G08	Inhibitor of NF-κB upregulates IκBα normal half-life	-2.604	4.065
<i>Lipopolysaccharide binding*†</i>	<i>Lbp</i>	H3086G08	Activates NF-κB via MAPK	-2.977	2.103
<i>Phosphoprotein enriched†</i>	<i>Pea15</i>	H3014G07	Inducer of NF-κB	-2.424	1.159
<i>Pyruvate dehydrogenase*†</i>	<i>Pdha1</i>	H3068G07	NF-κB site in promoter	-3.021	1.643
<i>Sterol carrier protein 2*†</i>	<i>Scp2</i>	H3122F12		-2.412	1.488
Stress response					
<i>Crystallin α 2</i>	<i>Crya2</i>	H3143B04	Inhibitor NF-κB	-3.921	3.479
Signal transduction					
<i>Adenylate kinase†</i>	<i>Ak2</i>	H3052D11		-3.755	3.546
<i>Max dimerization protein 4*†</i>	<i>Mad4</i>	H3131B07		-2.008	2.131
<i>MAD homolog 4</i>	<i>Madh4</i>	H3128C04		-2.765	2.114
<i>NF-κB enhancer inhibitor*</i>	<i>Nfkbia</i>	H3026A08		-1.433	4.611
<i>NIK-related kinase</i>	<i>Nrk</i>	H3008B02	Activates NF-κB	-2.244	4.859
<i>Phosphoglycerate kinase*</i>	<i>Pgk1</i>	H3023D06		-2.659	2.061
<i>Protein tyrosine phosphatase 4</i>	<i>Ptp4a2</i>	H3088F03		-2.118	1.615
<i>Rho-associated coiled-coil</i>	<i>Rock1</i>	H3069C09		-2.808	3.183
<i>TNF receptor associated factor</i>	<i>Traf1</i>	H3015E06	NF-κB dependent	-2.011	1.243
Nuclear proteins/transcription factors					
<i>Cbp/p300 interacting transactivation</i>	<i>Cited4</i>	H3076H08	NF-κB co-activator	-2.178	2.745
<i>High mobility group box 1</i>	<i>Hmgbl</i>	H3126A05	Binds p50 subunit	-3.104	1.739
<i>Jun oncogene</i>	<i>Jun</i>	H3058C09	NF-κB co-activator	-2.906	2.057
<i>Ras-related C3</i>	<i>Rac1</i>	H3018C09	Inducer of NF-κB	-2.004	3.329
RNA processing					
<i>Nuclear protein 220†</i>	<i>Np220</i>	H3029A07		-2.259	1.827
<i>RNA polymerase II*</i>	<i>Rpo2-3</i>	H3055H08	Coactivator of p65	-2.639	4.501
Protein synthesis/modification					
<i>Eukaryotic translation 4g2</i>	<i>Eif4g2</i>	H3113E10		-4.698	2.222
<i>Nedd4 WW-binding protein 4*</i>	<i>N4wbp4</i>	H3062G06		-6.966	2.814
Structural proteins					
<i>Alpha 2 glycoprotein 1*†</i>	<i>Azgp1</i>	IMAGE:521249		-2.013	1.398
<i>Beta spectrin 2*†</i>	<i>Spm2</i>	H3010G09		-3.781	1.015
<i>Catenin beta*</i>	<i>Catnb</i>	H3031E05	Regulated by IKK	-3.998	3.061
<i>Fibronectin†</i>	<i fn1<="" i=""></i>	H3116A10	NF-κB site in promoter	-6.201	4.723
<i>Catenin α 1*†</i>	<i>Catnal</i>	H3018E08		-1.996	1.723
<i>Tenascin C</i>	<i>Tnc</i>	L0062E01	NF-κB site in promoter	-2.557	1.956
Other					
<i>Deleted in polyposis</i>	<i>Dp1</i>	J0420H06		-2.473	2.137
<i>Insulin-like growth factor r2</i>	<i>Igfr2</i>	H3148G08		-2.765	2.494
<i>Ninjurin 1*</i>	<i>Ninj1</i>	H3072B10		-2.579	4.878
<i>Rabaptin 5*†</i>	<i>Rab5ep</i>	H3002C01		-2.739	1.333
<i>Topoisomerase II α*†</i>	<i>Top2a</i>	H3139A05	Inducer of NF-κB	-2.427	2.893
<i>Tumor differentially expressed†</i>	<i>Tde11</i>	H3014H10		-2.593	1.18
<i>WW domain binding 5*</i>	<i>Wbp5</i>	H3127H02		-2.087	3.313
<i>Zinc finger protein 68*†</i>	<i>Zfp68</i>	H3058F07		-4.122	5.885

NOTE. Number of genes regulated by NF-κB = 47/141. Number of genes previously associated with NF-κB = 39/141.

* Genes containing κB site in promoter region.

† Genes containing ACTACAG motif in coding sequence.